Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.37 +0.29 (+1.07%)
Official Closing Price Updated: 7:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
Pfizer Tries To Fatten Its Profits With Weight Loss Drugs
Pfizer needs to fortify its future revenues. 
Via Talk Markets
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
From Pfizer Inc.
Via Business Wire
3 Top Dividend Stocks to Buy and Hold Forever
These blue chip dividend stocks offer both income and growth potential. 
Via The Motley Fool
Topics Intellectual Property
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
What's Driving the Market Sentiment Around Pfizer?
 
Via Benzinga
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months. 
Via Investor's Business Daily
Topics Intellectual Property
The Smartest Dividend Stock to Buy With $1,000 Right Now
Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option. 
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives. 
Via The Motley Fool
Topics Intellectual Property
Where Will Pfizer Be in 5 Years?
The pharma giant may be heading for a new era of growth. 
Via The Motley Fool
Topics Intellectual Property
Time To Buy Pfizer Or Metsera Stock?
Making a major move in the obesity drug market, Pfizer announced on Monday that it plans to acquire biotechnology firm Metsera by the end of the year for $4.9 billion or $47.50 a share. 
Via Talk Markets
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety? 
Via The Motley Fool
3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer
Each of these dividend payers sports a fat yield of more than 6.5%. 
Via The Motley Fool
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Pfizer's plan to enter the booming obesity market took an expensive new turn. 
Via The Motley Fool
Prediction: Warren Buffett Is Retiring in 100 Days, and 3 Big Changes Are Coming to Berkshire Hathaway When He Does
The post-Warren Buffett era for Berkshire Hathaway will look quite different. 
Via The Motley Fool
Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records
Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant. 
Via Chartmill
Topics Economy
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current... 
Via Benzinga
Topics Government
Why BioNTech Stock Bumped Higher Today
Investors were cheered by two pieces of good news concerning the biotech's most famous product. 
Via The Motley Fool
Curious about the most active S&P500 stocks in today's session?
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest... 
Via Chartmill
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
MTSR Shares Jump After Pfizer Merger Agreement
Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies. 
Via Talk Markets
Why Pfizer Stock Just Popped
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
From Brodsky & Smith LLC
Via GlobeNewswire
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Gold Gains Over 1%; Quantum Computing Shares Plunge
 
Via Benzinga
IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance
The company is focusing on RNA sequencing as a means of assisting with drug development. 
Via Investor's Business Daily
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.